Scientists test drug duo to boost lymphoma treatment power
NCT ID NCT07138547
Summary
This study is testing whether adding an oral drug called Eliglustat makes existing CD30-targeted immunotherapies work better against CD30-positive lymphoma. It will enroll about 40 adults who have had at least one prior treatment. The main goals are to see if the combination is safe and if it helps more patients achieve remission or live longer without their cancer progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
People's Liberation Army General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.